LiPlasome Pharma
Vejle
About LiPlasome Pharma
LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis®, Oxaliplatin -> LiPloxa. The aim is to provide more effective treatment to cancer patients with fewer side effects.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2005)
- Website: liplasome.com
- Phone: 45 88 70 80 20
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Canonical: https://fsome.com/organization/liplasome-pharma-1749305 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.